

Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

Vladimirs Pilipenko¹

¹ University of Latvia

Potential competing interests: No potential competing interests to declare.

This article describes in a concise and thorough way the intranasal administration of Isoeugenol in transgenic APP/PS1 model of familial AD. Although the article is well articulated and constructed, what gathered my attention is the lack of power analysis. In my opinion, the article will benefit from it, as it will provide a rationale for selected numbers of animals. Also, it would be marvellous if authors could state whether all data were normalized. Otherwise I find the manuscript excellent and suitable for publication.